{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T04:08:17Z","timestamp":1768968497187,"version":"3.49.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2015,5,27]],"date-time":"2015-05-27T00:00:00Z","timestamp":1432684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7,1]]},"DOI":"10.1002\/ejhf.296","type":"journal-article","created":{"date-parts":[[2015,5,27]],"date-time":"2015-05-27T12:58:01Z","timestamp":1432731481000},"page":"647-651","source":"Crossref","is-referenced-by-count":2,"title":["Disrupting Virchow\u2019s Triad: Can Factor X Inhibition Reduce Risk of Adverse Outcomes in Patients with Ischaemic Cardiomyopathy?"],"prefix":"10.1093","volume":"17","author":[{"given":"Tariq","family":"Ahmad","sequence":"first","affiliation":[{"name":"Section of Cardiology, Yale University School of Medicine , New Haven, CT ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Stony Brook University , Stony Brook, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,5,27]]},"reference":[{"key":"2026011921092850300_ejhf296-bib-0001","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2141.2008.07323.x","article-title":"Virchow and his triad: a question of attribution","volume":"143","author":"Bagot","year":"2008","journal-title":"Br J Haematol"},{"key":"2026011921092850300_ejhf296-bib-0002","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s10741-012-9343-x","article-title":"Anticoagulation in heart failure: current status and future direction","volume":"18","author":"Gheorghiade","year":"2013","journal-title":"Heart Fail Rev"},{"key":"2026011921092850300_ejhf296-bib-0003","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026011921092850300_ejhf296-bib-0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2013.07.007","article-title":"Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives","volume":"2","author":"Gurbel","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026011921092850300_ejhf296-bib-0005","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.266","article-title":"Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction, or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial","volume":"17","author":"Zannad","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011921092850300_ejhf296-bib-0006","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/eurjhf\/hfs171","article-title":"Updated meta-analysis on antithrombotic therapy in patients with heart failure and sinus rhythm","volume":"15","author":"Hopper","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011921092850300_ejhf296-bib-0007","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ahj.2004.03.010","article-title":"The warfarin\/aspirin study in heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure","volume":"148","author":"Cleland","year":"2004","journal-title":"Am Heart J"},{"key":"2026011921092850300_ejhf296-bib-0008","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejheart.2006.02.012","article-title":"Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study","volume":"8","author":"Cokkinos","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"2026011921092850300_ejhf296-bib-0009","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1161\/CIRCULATIONAHA.108.801753","article-title":"Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the warfarin and antiplatelet therapy in chronic heart failure (WATCH) trial","volume":"119","author":"Massie","year":"2009","journal-title":"Circulation."},{"key":"2026011921092850300_ejhf296-bib-0010","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1056\/NEJMoa1202299","article-title":"Warfarin and aspirin in patients with heart failure and sinus rhythm","volume":"366","author":"Homma","year":"2012","journal-title":"N Engl J Med"},{"key":"2026011921092850300_ejhf296-bib-0011","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/eurjhf\/hfs073","article-title":"Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis","volume":"14","author":"Lip","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026011921092850300_ejhf296-bib-0012","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2026011921092850300_ejhf296-bib-0013","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1161\/CIRCULATIONAHA.114.013760","article-title":"Risk of stroke in chronic heart failure patients without atrial fibrillation: analysis of the CORONA and GISSI-HF trials","volume":"131","author":"Abdul-Rahim","year":"2015","journal-title":"Circulation"},{"key":"2026011921092850300_ejhf296-bib-0014","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jacc.2012.10.025","article-title":"Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial","volume":"61","author":"Butler","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011921092850300_ejhf296-bib-0015","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.jacc.2014.07.979","article-title":"Clinical implications of chronic heart failure phenotypes defined by cluster analysis","volume":"64","author":"Ahmad","year":"2014","journal-title":"J Am Coll Cardiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.296","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/17\/7\/647\/66422666\/eurjhf_17_7_647.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/17\/7\/647\/66422666\/eurjhf_17_7_647.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:09:49Z","timestamp":1768874989000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/17\/7\/647\/8426503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,27]]},"references-count":15,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,5,27]]},"published-print":{"date-parts":[[2015,7,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.296","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,7]]},"published":{"date-parts":[[2015,5,27]]}}}